Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

Becton Dickinson ( ($BDX) ) has issued an announcement. On May 11, 2026, Becton, Dickinson and Company and its Luxembourg-based financing subsidiar...

Becton Dickinson Announces €600 Million Senior Notes Offering

In a report released on May 8, Rick Wise from Stifel Nicolaus maintained a Buy rating on Becton Dickinson, with a price target of $175.00. The comp...

Stifel Nicolaus Sticks to Its Buy Rating for Becton Dickinson (BDX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Becton Dickinson (BDX) wi...

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Becton Dickinson (BDX)

The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has appointed seasoned medical technology executive An...

BCAL taps industry veteran Anne-Louise Arnett to spearhead cancer diagnostics rollout

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Becton Dickinson (BDX), Immunocore Holdings (IMCR) and Eli Lilly ...

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Immunocore Holdings (IMCR) and Eli Lilly & Co (LLY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDX) and Glaukos (GKOS). Becton ...

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX) and Glaukos (GKOS)

Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. The clinical study “An Investigational Study to Evaluate the S...

BD’s PosiFlush SafeScrub Study Completion: What Investors Should Watch Next

In a report released today, Jason Bednar from Piper Sandler maintained a Hold rating on Becton Dickinson, with a price target of $159.00. According...

Current Quarter	$3.11	Next Quarter	$4.05
Current Year	$12.59	Next Year	$13.8
QoQ Growth	+30.2%	YoY Growth	+9.6%
3Y EPS CAGR	-0.5%	Target Price	$180.50
Consensus	Buy	Upside	+22.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$147.51	+3.05%	3.47M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$147.51	+3.0%	3.47M
3
4
5
6

BDX

BDX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel